Literature DB >> 26492962

The economic burden of musculoskeletal disorders on the Italian social security pension system estimated by a Monte Carlo simulation.

S Russo1, T T Mariani, R Migliorini, A Marcellusi, F S Mennini.   

Abstract

The aim of the study is to estimate the pension costs incurred for patients with musculoskeletal disorders (MDs) and specifically with rheumatoid arthritis (RA) and ankylosing spondylitis (AS) in Italy between 2009 and 2012. We analyzed the database of the Italian National Social Security Institute (Istituto Nazionale Previdenza Sociale i.e. INPS) to estimate the total costs of three types of social security benefits granted to patients with MDs, RA and AS: disability benefits (for people with reduced working ability), disability pensions (for people who cannot qualify as workers) and incapacity pensions (for people without working ability). We developed a probabilistic model with a Monte Carlo simulation to estimate the total costs for each type of benefit associated with MDs, RA and AS. We also estimated the productivity loss resulting from RA in 2013. From 2009 to 2012 about 393 thousand treatments were paid for a total of approximately €2.7 billion. The annual number of treatments was on average 98 thousand and cost in total €674 million per year. In particular, the total pension burden was about €99 million for RA and €26 million for AS. The productivity loss for AR in 2013 was equal to €707,425,191 due to 9,174,221 working days lost. Our study is the fi rst to estimate the burden of social security pensions for MDs based on data of both approved claims and benefits paid by the national security system. From 2009 to 2012, in Italy, the highest indirect costs were associated with disability pensions (54% of the total indirect cost), followed by disability benefits (44.1% of cost) and incapacity pensions (1.8% of cost). In conclusion, MDs are chronic and highly debilitating diseases with a strong female predominance and very significant economic and social costs that are set to increase due to the aging of the population.

Entities:  

Mesh:

Year:  2015        PMID: 26492962     DOI: 10.4081/reumatismo.2015.811

Source DB:  PubMed          Journal:  Reumatismo        ISSN: 0048-7449


  4 in total

1.  Economic Burden of Rheumatoid Arthritis in Italy: Possible Consequences on Anti-Citrullinated Protein Antibody-Positive Patients.

Authors:  Francesco Saverio Mennini; Andrea Marcellusi; Lara Gitto; Florenzo Iannone
Journal:  Clin Drug Investig       Date:  2017-04       Impact factor: 2.859

2.  Economic burden of schizophrenia in Italy: a probabilistic cost of illness analysis.

Authors:  Andrea Marcellusi; Gianluca Fabiano; Raffaella Viti; Pier Cesare Francesa Morel; Giuseppe Nicolò; Alberto Siracusano; Francesco Saverio Mennini
Journal:  BMJ Open       Date:  2018-02-08       Impact factor: 2.692

3.  Health and Economic Impact of Atrial Fibrillation of Workers in Italy: Social Security Benefits.

Authors:  Marco Trabucco Aurilio; Francesco Saverio Mennini; Claudia Nardone; Andrea Piccioni; Matteo Bolcato; Vincenzo Russo; Valerio Sciannamea; Raffaele Migliorini; Luca Coppeta; Andrea Magrini
Journal:  Int J Environ Res Public Health       Date:  2022-02-08       Impact factor: 3.390

4.  Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada.

Authors:  Laure Weijers; Christoph Baerwald; Francesco S Mennini; José M Rodríguez-Heredia; Martin J Bergman; Denis Choquette; Kirsten H Herrmann; Giulia Attinà; Carmela Nappi; Silvia Jimenez Merino; Chad Patel; Mondher Mtibaa; Jason Foo
Journal:  Rheumatol Int       Date:  2017-05-30       Impact factor: 2.631

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.